Kardi Ai, a Czech medtech company focused on long-term ECG monitoring, has raised €5.3 million ($5.7 million) in a Series A funding round to accelerate its international expansion and advance its artificial intelligence capabilities for heart rhythm monitoring.
The financing round was led by Callisto Health, with participation from Česká spořitelna, Slovenská sporiteľňa (through Seed Starter), BrightCap Ventures, Purple Ventures, DEPO Ventures, and Garage Angels. The capital injection marks a significant milestone for the Prague-based startup as it scales operations beyond its home market.
Expansion Strategy and Market Opportunity
Kardi Ai plans to deploy the fresh funding across multiple strategic priorities. The company will expand its footprint across European markets including Germany, Poland, Romania, Bulgaria, and Slovakia, while simultaneously launching operations in Asia across India, the United Arab Emirates, and Singapore. These expansion efforts represent a substantial geographic diversification for the medtech startup.
Beyond market expansion, the startup will invest in developing advanced predictive AI models designed to detect early signs of arrhythmias before they manifest clinically. This shift from reactive detection to predictive intervention reflects a broader trend in digital health toward preventive care models. The company will also pursue necessary regulatory approvals to operate across its target markets.
According to Vlastimil Hrabal, the company’s leadership, the vision extends beyond traditional arrhythmia detection. “We are gradually moving beyond detecting heart rhythm disorders towards technology capable of identifying an increased risk before arrhythmia manifests. Nearly two billion people live in the markets where we already operate or are preparing to launch. The new capital will allow us to validate this technology at global scale and across patient demographics and pursue our ambition to become a leading provider of long-term ECG monitoring in these markets,” Hrabal stated.
Positioning in the Healthtech Landscape
The investment underscores growing investor confidence in European medtech solutions targeting cardiovascular health, a critical area where remote monitoring and AI-driven diagnostics continue to attract significant capital. Cardiac arrhythmias affect millions globally and represent a substantial healthcare burden, creating substantial commercial opportunity for effective monitoring solutions.
Kardi Ai’s approach of combining long-term ECG monitoring with machine learning algorithms positions it within a competitive but expanding segment of the digital health market. The company’s focus on expanding into emerging markets suggests confidence in the universal applicability of its platform, though this strategy also requires navigating diverse regulatory frameworks across regions.
The Czech Republic continues to establish itself as a notable player in the European healthtech ecosystem, with several startups attracting international investor attention. Kardi Ai’s Series A round demonstrates sustained investor appetite for health technology innovations emerging from Central Europe, contributing to the region’s growing reputation for medtech innovation alongside larger Western European hubs.